Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 10:03AM EDT. Market open.
| Previous Close | 51.18 |
| Open | 50.90 |
| Bid | 51.38 x 600 |
| Ask | 51.58 x 300 |
| Day's Range | 50.87 - 51.76 |
| 52 Week Range | 50.27 - 75.74 |
| Volume | |
| Avg. Volume | 1,768,538 |
| Market Cap | 11.55B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 19.41 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
- Zacks
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
- Zacks
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2024 Yahoo. All rights reserved.